In a preclinical NASH model, treatment with the selective Axl inhibitor bemcentinib reduces NASH-associated fibrosis and concomitantly increases Gas6, suggesting a compensatory mechanism of hepatoprotective MerTK activation [121,133]. Here, GAS6 is linked to metabolic dysfunction-associated steatohepatitis.